Tarsier pharma will be participating at the 10th International Symposium on Uveitis, of the International Uveitis Study Group (IUSG), taking place in the Netherlands and virtually (in a hybrid format), on August 25-27, 2022.
The IUSG comprises of clinicians and researchers who are committed to stimulate, encourage and intensify a concerted effort in research and clinical management of uveitis. It organizes the International Symposium on Uveitis every four years, featuring keynote and plenary lectures, symposiums, papers, round-table discussions, and more. It is a central event for networking and becoming up to date on uveitis global research and developments.
Tarsier Pharma’s CEO and Chairperson, Dr. Daphne Haim-Langford, will participate at the event, and together with Advisory Board Member, Prof. de Smet, who is also a member of the IUSG, they will host a session about uveitic glaucoma and Tarsier’s development, targeting this indication. The session is called “Uveitic Glaucoma – Medical challenge and potential new non-steroidal treatment” and will take place during the lunch symposium about future technologies and innovations, on 27 August, 12:25pm, Room 1.